

UROLIFT®

BPH Relief. In Sight.™

AUA Virtual Science Event 2020

UroLift® System Highlights

The studies represented are sponsored by NeoTract Inc./Teleflex

Real World Retrospective Study – Dr. Gregg Eure

Objective: To assess UroLift® System performance in a heterogenous real-world population compared to experience in controlled settings


Study Design

- Data from the Real World Retrospective (RWR) Study was compared to the LIFT and PULSAR (retention) controlled studies
 - Update to the UroLift System RWR study published in 2019. Larger sample size with 3,226 patients across 22 sites in USA, UK & Australia
- Evaluated the following clinical outcomes across the studies:
 - IPSS, QoL, Qmax
 - Adverse events including dysuria, hematuria, pelvic pain and blood clots
 - Catheterization

Real World Retrospective Study – Dr. Gregg Eure

Results

- Similar absolute IPSS scores among all groups at all timepoints
- Post-op cath-free rate higher in RWR (90%) vs. L.I.F.T. (68%)
 - *Note: these rates excluded catheters placed at discretion of urologist or standard protocol*
- Majority of retention patients become catheter independent
 - 81% in RWR vs. 60% in PULSAR (1 month)
 - 84% in RWR vs. 73% in PULSAR (study end)



(1 month, $p=0.4$; 3 months, $p=0.3$; 6 months, $p=0.2$; 12 months, $p=0.5$)

Conclusions

- UroLift® System real world outcomes are largely consistent with results from controlled trials
- UroLift System has broad applicability to treat heterogenous populations of non-retention and retention subjects in the real world

Sexual Function Study – Dr. Claus Roehrborn


Objective: Compare sexual health outcomes following the UroLift® System or medical therapy

Study Design

- Indirect comparison of sexual health outcomes from the MTOPS and UroLift® System studies (LIFT, Crossover, MedLift)
 - MTOPS patients matched to LIFT criteria (IPSS ≥ 13 , Qmax ≤ 12 ml/sec, prostate 30-80cc)
- Sexual health assessment was done through BMSFI in MTOPS study and IIEF & MSHQ-EjD in UroLift studies
 - Common questions were used for comparisons and % change in response was calculated

Sexual Function Study – Dr. Claus Roehrborn

Results



UroLift® System procedure was superior to Finasteride and Combo at preserving erectile function at 1 and 2 years

UroLift System procedure outperformed all medical treatments at all time points at preserving ejaculatory function

Only UroLift System procedure significantly improved sexual satisfaction through 4 years

Conclusions

- Patients treated with the UroLift® System achieved better outcomes in sexual function* and satisfaction than men who received medical therapy

* Erectile & ejaculatory function